1
|
Lee J, Kim B, Kim TH, Lee SH, Park HD, Chung K, Lee SH, Paek S, Kim EE, Yoon S, Kim A. A Food Effect Study of an Oral Thrombin Inhibitor and Prodrug Approach To Mitigate It. Mol Pharm 2016; 13:1197-205. [PMID: 26886576 DOI: 10.1021/acs.molpharmaceut.5b00637] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
LB30870, a new direct thrombin inhibitor, showed 80% reduction in oral bioavailability in fed state. The present study aims to propose trypsin binding as a mechanism for such negative food effect and demonstrate a prodrug approach to mitigate food effect. Effect of food composition on fed state oral bioavailability of LB30870 was studied in dogs. Various prodrugs were synthesized, and their solubility, permeability, and trypsin binding affinity were measured. LB30870 and prodrugs were subject to cocrystallization with trypsin, and the X-ray structures of cocrystals were determined. Food effect was studied in dogs for selected prodrugs. Protein or lipid meal appeared to affect oral bioavailability of LB30870 in dogs more than carbohydrate meal. Blocking both carboxyl and amidine groups of LB30870 resulted in trypsin Ki values orders of magnitude higher than that of LB30870. Prodrugs belonged to either Biopharmaceutical Classification System I, II, or III. X-ray crystallography revealed that prodrugs did not bind to trypsin, but instead their hydrolysis product at the amidine blocking group formed cocrystal with trypsin. A prodrug with significantly less food effect than LB30870 was identified. Binding of prodrugs to food components such as dietary fiber appeared to counteract the positive effect brought with the prodrug approach. Further formulation research is warranted to enhance the oral bioavailability of prodrugs. In conclusion, this study is the first to demonstrate that the negative food effect of LB30870 can be attributed to trypsin binding. Trypsin binding study is proposed as a screening tool during lead optimization to minimize food effect.
Collapse
Affiliation(s)
- Jihye Lee
- College of Pharmacy, CHA University , 521 CHA Bio Complex, 335 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do 13488, Korea
| | - Bongchan Kim
- LG Life Sciences, R&D Center ,188, Munji-ro, Yuseong-gu, Daejeon 34122, Korea
| | - Tae Hun Kim
- LG Life Sciences, R&D Center ,188, Munji-ro, Yuseong-gu, Daejeon 34122, Korea
| | - Sun Hwa Lee
- LG Life Sciences, R&D Center ,188, Munji-ro, Yuseong-gu, Daejeon 34122, Korea
| | - Hee Dong Park
- LG Life Sciences, R&D Center ,188, Munji-ro, Yuseong-gu, Daejeon 34122, Korea
| | - Kyungha Chung
- LG Life Sciences, R&D Center ,188, Munji-ro, Yuseong-gu, Daejeon 34122, Korea
| | - Sung-Hack Lee
- LG Life Sciences, R&D Center ,188, Munji-ro, Yuseong-gu, Daejeon 34122, Korea
| | - Seungyup Paek
- LG Life Sciences, R&D Center ,188, Munji-ro, Yuseong-gu, Daejeon 34122, Korea
| | - Eunice EunKyeong Kim
- Korea Institute of Science and Technology, Hwarangno 14-gil 5, Seongbuk-gu, Seoul 02792, Korea
| | - SukKyoon Yoon
- New Drug Development Center, Daegu-Gyeongbuk Medical Innovation Foundation , 41061 Daegu, Korea
| | - Aeri Kim
- College of Pharmacy, CHA University , 521 CHA Bio Complex, 335 Pangyo-ro, Bundang-gu, Seongnam-si, Gyeonggi-do 13488, Korea
| |
Collapse
|
2
|
Kim J, Lee SH, Boyce M, Warrington S, Cho KH, Yoon SK, Park HD, Kim A. Pharmacokinetics, pharmacodynamics and food effect of LB30870, a novel direct thrombin inhibitor, after single oral doses in healthy men. Xenobiotica 2015; 45:663-71. [PMID: 25673087 DOI: 10.3109/00498254.2015.1010110] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
1. The safety, tolerability, pharmacokinetics, pharmacodynamics, and food effect of LB30870, a new selective thrombin inhibitor, were studied in 16 healthy men. 2. A double-blind, placebo-controlled single ascending dose study was done at oral doses of 5, 15, 30, 60, 120, and 240 mg under fasting conditions. An open, randomized, balanced cross-over food effect study was done at 60 mg dose. Plasma and urinary concentrations were measured up to 48 h post-dose. Coagulation and thrombin activity markers were measured at selected time points. 3. Cmax of LB30870 was at 1.3-3.0 h post-dose with a mean apparent terminal half-life (t1/2) of 2.8-4.1 h. AUC after doses above 15 mg appeared greater than dose-proportional. In fed state, AUC showed 80% reduction relative to fasting condition. 4. At doses 60 and 120 mg, peak activated partial thromboplastin time (aPTT) increased by 1.5- and 2-fold, respectively, from baseline. The aPTT and international normalized ratio (INR) were concentration-dependent, with less within-individual variability than ecarin clotting time (ECT), prothrombin time (PT), or thrombin time (TT). 5. Single oral doses of LB30870 up to 240 mg were well tolerated. The food effect must be overcome if LB30870 is to be used as an oral anti-coagulant.
Collapse
Affiliation(s)
- John Kim
- Drug Metabolism & Pharmacokinetics, LG Life Sciences , Daejeon , Korea
| | | | | | | | | | | | | | | |
Collapse
|
3
|
Park HD, Lee SH, Kim TH, Lee SH, Cho KH, Kim A. Antithrombotic effects of LB30870, a potent, orally active, selective and direct thrombin inhibitor, and pharmacokinetics of its prodrug. Bioorg Med Chem Lett 2013; 23:4779-84. [DOI: 10.1016/j.bmcl.2013.07.008] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/13/2013] [Revised: 06/17/2013] [Accepted: 07/02/2013] [Indexed: 10/26/2022]
|